In the KEYNOTE-859 trial, the superiority of pembrolizumab plus chemotherapy (CAPOX or FP) over chemotherapy alone in patients with previously untreated HER2-negative mG/GEJ cancer was evaluated. The gene discussed is ERBB2; the disease is cancer.